Maine 2025-2026 Regular Session

Maine Senate Bill LD890

Introduced
3/4/25  
Refer
3/4/25  

Caption

An Act to Permit the Dispensing of Ivermectin Pursuant to a Standing Order upon Request for COVID-19, Flu and Cancer Patients

Impact

Should LD890 be passed, it would allow pharmacists to dispense ivermectin following a standing order from a licensed practitioner. This standing order must detail the authorization for the specific usage of ivermectin in treating the aforementioned diseases, as well as documentation requirements to ensure patients are screened properly. The changes proposed by the bill may enhance the role of pharmacists in providing immediate care to patients seeking treatment, potentially improving health outcomes for those affected by these serious illnesses.

Summary

LD890, known as An Act to Permit the Dispensing of Ivermectin Pursuant to a Standing Order upon Request for COVID-19, Flu and Cancer Patients, aims to allow pharmacists to dispense ivermectin without a prescription under specified conditions. This measure is framed within the context of treating patients with COVID-19, influenza, or cancer, thus seeking to provide easier access to this medication in a pharmacy setting. The initiative could lead to changes in how certain treatments are administered in the state, particularly in pharmacies where patients can directly request ivermectin.

Sentiment

The sentiment around the bill appears to be cautiously supportive among healthcare providers who advocate for increased access to treatments in a timely manner, especially for patients who are seriously ill. However, there are likely concerns regarding the implications of allowing a pharmacy-based distribution of ivermectin without a direct prescription, particularly considering debates surrounding the drug's efficacy and safety in treating COVID-19 and other conditions. Stakeholder perspectives may vary, with some viewing it as a necessary step towards patient empowerment and accessibility, while others may hold apprehensive views regarding safety and oversight.

Contention

The main points of contention surrounding LD890 are related to the regulatory oversight and potential misuse of ivermectin. While the bill aims to provide patients with quicker access to treatments, critics may voice concerns about the implications of pharmacists dispensing medications that traditionally require a prescription. This could lead to debates on professional boundaries within pharmacy practice, the necessity of direct medical supervision, and the potential for adverse effects if the medications are not used appropriately.

Companion Bills

No companion bills found.

Similar Bills

MS HB1288

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

MS HB1300

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

MS HB1511

Ivermectin; authorize pharmacists to provide to adults pursuant to collaborative pharmacy practice agreement.

LA HB312

Provides relative to the over-the-counter sale and purchase of the drug ivermectin without a prescription

NH HB1022

Permitting pharmacists to dispense the drug Ivermectin by means of a standing order and establishing a commission to study the use of Ivermectin to treat Covid-19.

WV SB614

Authorizing over-the-counter sale of Ivermectin

AL HB278

Pharmacists, allow to dispense ivermectin without a prescription

AL HB499

Relating to prescription drugs; to provide for the dispensing of Ivermectin by a pharmacist without an individual prescription pursuant to a standing order issued by a physician, physician's assistant, or certified registered nurse practitioner; to protect physicians, physician's assistants, certified registered nurse practitioners, and pharmacists from licensure disciplinary action due to dispensing Ivermectin.